(Q55239686)

28 June 2018

title

Trends in residual risk of transfusion-transmitted viral infections in France between 1992 and 2000. (English)

1 reference

28 June 2018

main subject

Syria

0 references

author

Jean-Claude Desenclos

4

object named as

Jean-Claude Desenclos

1 reference

28 June 2018

author name string

Josiane Pillonel

1

1 reference

28 June 2018

Syria Laperche

2

1 reference

28 June 2018

Christine Saura

3

1 reference

28 June 2018

Anne-Marie Couroucé

5

1 reference

28 June 2018

Transfusion-Transmissible Agents Working Group of the French Society of Blood Transfusion

6

1 reference

28 June 2018

publication date

1 August 2002

1 reference

28 June 2018

published in

Transfusion

1 reference

28 June 2018

volume

42

1 reference

28 June 2018

issue

8

1 reference

28 June 2018

page(s)

980-988

1 reference

28 June 2018

The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1537-2995.2002.00155.X

A method for estimating hepatitis B virus incidence rates in volunteer blood donors. National Heart, Lung, and Blood Institute Retrovirus Epidemiology Donor Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1537-2995.2002.00155.X

Time course of detection of viral and serologic markers preceding human immunodeficiency virus type 1 seroconversion: implications for screening of blood and tissue donors

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1537-2995.2002.00155.X

A prospective study of transmission by transfusion of HTLV-I and risk factors associated with seroconversion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1537-2995.2002.00155.X

Improved detection of anti-HCV in post-transfusion hepatitis by a third-generation ELISA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1537-2995.2002.00155.X

Effect of concurrent acute infection with hepatitis C virus on acute hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1537-2995.2002.00155.X

False-negative testing errors in routine viral marker screening of blood donors. For the Retrovirus Epidemiology Donor Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1537-2995.2002.00155.X

Screening for markers of infections transmitted by transfusions in the blood collected in France from 1996 to 1998

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1537-2995.2002.00155.X

Sensitivity of United States HIV antibody tests for detection of HIV-1 group O infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1537-2995.2002.00155.X

HIV-1/HIV-2 seronegativity in HIV-1 subtype O infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1537-2995.2002.00155.X

HIV-1 diversity in France, 1996-1998. The AC 11 laboratory network

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1537-2995.2002.00155.X

Evaluation of United States-licensed human immunodeficiency virus immunoassays for detection of group M viral variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1537-2995.2002.00155.X

Evidence of hepatitis C virus viremia without detectable antibody to hepatitis C virus in a blood donor

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1537-2995.2002.00155.X

New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1537-2995.2002.00155.X

Screening of blood donations for HTLV-I/II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1537-2995.2002.00155.X

How much would the safety of blood transfusion be improved by including p24 antigen in the battery of tests?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1537-2995.2002.00155.X

Duration of time from onset of human immunodeficiency virus type 1 infectiousness to development of detectable antibody. The HIV Seroconversion Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1537-2995.2002.00155.X

Post-Transfusion Hepatitis C Virus Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1537-2995.2002.00155.X

The prevalence of hepatitis C virus infection in the United States, 1988 through 1994

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1537-2995.2002.00155.X

Hepatitis C in a French population-based survey, 1994: seroprevalence, frequency of viremia, genotype distribution, and risk factors. The Collaborative Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1537-2995.2002.00155.X

Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1537-2995.2002.00155.X

Testing of individual blood donations for HCV RNA reduces the residual risk of transfusion-transmitted HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1537-2995.2002.00155.X

Risk-benefit analysis of nucleic acid testing: the French experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1537-2995.2002.00155.X

10.1046/J.1537-2995.2002.00155.X

21 January 2018

Identifiers

DOI

1 reference

28 June 2018

1 reference

28 June 2018